These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 17056061)

  • 1. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
    J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
    Hsiou Y; Das K; Ding J; Clark AD; Kleim JP; Rösner M; Winkler I; Riess G; Hughes SH; Arnold E
    J Mol Biol; 1998 Nov; 284(2):313-23. PubMed ID: 9813120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
    J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
    La Regina G; Coluccia A; Silvestri R
    Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.
    Chan AH; Lee WG; Spasov KA; Cisneros JA; Kudalkar SN; Petrova ZO; Buckingham AB; Anderson KS; Jorgensen WL
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9725-9730. PubMed ID: 28827354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
    Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
    FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
    Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
    Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
    Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
    J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Evanseck JD; Madura JD
    J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.
    Hachiya A; Marchand B; Kirby KA; Michailidis E; Tu X; Palczewski K; Ong YT; Li Z; Griffin DT; Schuckmann MM; Tanuma J; Oka S; Singh K; Kodama EN; Sarafianos SG
    J Biol Chem; 2012 Aug; 287(35):29988-99. PubMed ID: 22761416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
    Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
    Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
    Pelemans H; Esnouf RM; Jonckheere H; De Clercq E; Balzarini J
    J Biol Chem; 1998 Dec; 273(51):34234-9. PubMed ID: 9852086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.
    Ren J; Nichols CE; Chamberlain PP; Weaver KL; Short SA; Chan JH; Kleim JP; Stammers DK
    J Med Chem; 2007 May; 50(10):2301-9. PubMed ID: 17441703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
    Das K; Arnold E
    Curr Opin Virol; 2013 Apr; 3(2):111-8. PubMed ID: 23602471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Balzarini J; Gago F
    J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.